<DOC>
	<DOCNO>NCT01543321</DOCNO>
	<brief_summary>Late dyskinetic syndrome neuroleptic , tardive dyskinesia , appearance abnormal involuntary movement ( AIM ) patient treat antipsychotic least three month . This important public health issue arise 15-20 % patient treated neuroleptic , prescribe psychotropic drug mental disorder France , seriously impact patient ' quality life . In 50 % case , irreversible-that say persist despite discontinuation offend drug . Risk factor describe : age female gender establish , high dosage antipsychotic , long-term treatment , psychiatric condition schizophrenia likely risk factor , intermittent treatment , previous acute dyskinesia , neuroleptic powerful , long term use corrective treatment include anticholinergic still discuss . Apart preventive treatment , consist use antipsychotic coerce , support disappointing : etiological treatment , stop offend antipsychotic , effective less 50 % case , syndrome often late irreversible . Must still possibility interrupt treatment , usually impossible risk decompensation mental illness neuroleptic prescribed . Remains symptomatic treatment : functional neurosurgery extreme case , without risk , term morbidity mortality . So 's medication often offer : many drug propose , direct result multiplicity neurotransmitter system implicate . However , vast majority case , approach disappointing say ineffective . The exception tetrabenazine , market name XenazineÂ® . Empirically , neurologist specialize pathology movement almost unanimous : efficiency good , good tolerance . Some preliminary study reinforce impression . However , level evidence remain low investigator propose implement prospective multicenter clinical trial , double-blind placebo include two group 27 patient .</brief_summary>
	<brief_title>Xenazine Late Dyskinetic Syndrome With Neuroleptics</brief_title>
	<detailed_description>Tetrabenazine classify central monoamine deplete agent . In vitro study show inhibitor vesicular monamine transporter 2 ( VMAT2 ) , result synaptic dopamine depletion . This effect explain reduction hyperkinetic movement disorder . Although tetrabenazine enjoys reputation good efficacy tardive syndrome , good tolerance , still yet empiricism study andf importantly , low level evidence accord criterion Evidence Based Medicine . This randomized , multicenter , parallel group , double-blind placebo ( tetrabenazine/placebo : 1/1 ) , two comparative condition 10 week treatment tetrabenazine ( 5-week titration maximum dose 200 mg/day 5 week stable dose ) . Study enrollment propose patient fulfil inclusion criterion . The study process follow : 1 . Patients give informed consent participation presentation study investigator . 2 . Visit V0 : Given patient 's signed consent , global clinical examination , blood sampling , vital sign ( weight , height , arterial tension , ECG perform well neurological examination ( MMS ) . For woman childbearing potential , urinary pregnancy test realize . It noteworthy psychiatric consultation date less one month require . 3 . Visit V1 : patient randomize one two arm : tetrabenazine placebo . Some test perform baseline : - Neurologic : ESRS , AIMS , CGI , UPDRSIII , MMS ; - Quality life auto-questionnaires : SF36 , Epworth ; The treatment prescribe follow titration phase 5 week , stable dose 5 week , wash-out period 2 week . 4 . At V2 ( 1 week V1 ) , V3 ( 3 week V1 ) V5 ( 7 week V1 ) : global clinical examination perform prescription observance check . 5 . At V4 ( 5 week V1 ) , V6 ( 10 week V1 ) V7 ( 12 week V1 ) : neurological ( ESRS , AIMS , CGI , UPDRSIII , auto questionnaire SF36 , Epworth , neuropsychological examination ( MADRS ) , psychiatric examination ( V6 ) , vital sign prescription observance .</detailed_description>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Tetrabenazine</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1 . Adult ( age 18 ) adult judicial protection ( tutor curator ) . 2 . Patient late dyskinetic syndrome neuroleptic yield functional disability and/or impact every day 's life , accord investigator , and/or patient and/or patient 's family . 3 . Patient persistent late dyskinetic syndrome , even neuroleptic stop 6 month patient late dyskinetic syndrome neuroleptic treatment unchanged least 3 month would priori need dose variation study time . 4 . MADRS &lt; 18 5 . QTc &lt; 450 m men &lt; 470 woman . 1 . Lack social insurance 2 . Neuroleptic treatment le 3 month 3 . Insanity accord DSM IV MMS &lt; 24 4 . Predominant akathisia 5 . Psychiatric disease stabilize 6 month and/or could require neuroleptic treatment adaptation study time . 6 . Pregnancy lactate 7 . Women genital activity without efficient contraception method ( IUD estrogenprogestin pill ) 8 . Hypersensitivity tetrabenazine 9 . Renal failure 10 . Drugs : Nonselective MAOIs , dopaminergic ( antiparkinsonian ) 11 . Other severe pathology 12 . Patient non compliant protocol , investigator 's appreciation 13 . Simultaneous participation clinical trial 14 . Congenital galactosemia , glucose malabsorption lactase deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>tetrabenazine</keyword>
	<keyword>movement disorder</keyword>
	<keyword>tardive disorder</keyword>
</DOC>